Holding website  

  • About Us
    • What we do
      • Strategic Approach
    • Management Team
    • Collaboration & Partnering
    • Investors
    • Careers
      • Open Positions
        • Head of Medical Affairs
    • Privacy
  • APR Products
    • Prescription Healthcare Products
      • PKU GOLIKE® Family
      • Nexodyn® – Advanced Wound Care
        • Tehclo Technology
      • Diclofenac Immediate Release
        • Immediate Release Technology
        • Diclofenac 50 mg products
      • Ondansetron ODF
        • ODF Technology
        • Ondansetron ODF products
      • APR TD011 – Epidermolysis Bullosa
        • Tehclo Technology
      • APR TD012 – Hailey Hailey Disease
        • Tehclo Technology
      • APR 1204 – Ocular Surface Diseases
        • Tehclo Technology
      • Exelya®
        • Exelya®
        • Tehclo Technology
    • Consumer Healthcare Products
      • Acute Pain
        • Diclofenac 25 mg products
      • Healthy Aging – SwitzAge™
      • Pediatric
        • Halykoo
    • Therapeutical Areas
      • Inherited Metabolic Disorders
        • What is PKU (Phenylketonuria)?
      • Advanced Wound Care
        • Unmet Medical Need
      • Cancer Supportive Care
        • Nausea and vomiting
        • Oncodermatology
      • CNS (migraine)
      • Rare Dermatological Diseases
        • Epidermolysis Bullosa
        • Hailey Hailey Disease
      • Eye laser surgery
    • Pipeline
  • Our Services
    • Solid Dosage Forms
      • Oral Pharmaceuticals
        • Integrated project development
        • Project design planning
      • Oral Nutraceuticals
        • Integrated project development
        • Project design planning
      • Oral Medical Devices
        • Integrated project development
        • Project design planning
    • Non-Solid Dosage Forms
      • Topical Pharmaceuticals
        • Integrated project development
        • Project design planning
      • Topical Dermocosmetics
        • Integrated project development
        • Project design planning
      • Topical Medical Devices
        • Integrated project development
        • Project design planning
    • Analytical Services
    • Certifications
  • Media
    • Presentations
    • Press Releases
  • Contacts
    • Location
    • Vigilance
    • APR LAB

Discover who we are and our partners global network, as well as learn more about our people.

Learn more about our products and how they provide innovative solutions for patiens' unmet needs.

Discover our capabilities in project design services.

Find information such as website news, press releases and event presentations.

Get in touch with us to set up a meeting or propose your cooperation.

 
Non-Solid Dosage Forms
Topical Pharmaceuticals

Holding website  

  • About Us
    • What we do
      • Strategic Approach
    • Management Team
    • Collaboration & Partnering
    • Investors
    • Careers
      • Open Positions
        • Head of Medical Affairs
    • Privacy
  • APR Products
    • Prescription Healthcare Products
      • PKU GOLIKE® Family
      • Nexodyn® – Advanced Wound Care
        • Tehclo Technology
      • Diclofenac Immediate Release
        • Immediate Release Technology
        • Diclofenac 50 mg products
      • Ondansetron ODF
        • ODF Technology
        • Ondansetron ODF products
      • APR TD011 – Epidermolysis Bullosa
        • Tehclo Technology
      • APR TD012 – Hailey Hailey Disease
        • Tehclo Technology
      • APR 1204 – Ocular Surface Diseases
        • Tehclo Technology
      • Exelya®
        • Exelya®
        • Tehclo Technology
    • Consumer Healthcare Products
      • Acute Pain
        • Diclofenac 25 mg products
      • Healthy Aging – SwitzAge™
      • Pediatric
        • Halykoo
    • Therapeutical Areas
      • Inherited Metabolic Disorders
        • What is PKU (Phenylketonuria)?
      • Advanced Wound Care
        • Unmet Medical Need
      • Cancer Supportive Care
        • Nausea and vomiting
        • Oncodermatology
      • CNS (migraine)
      • Rare Dermatological Diseases
        • Epidermolysis Bullosa
        • Hailey Hailey Disease
      • Eye laser surgery
    • Pipeline
  • Our Services
    • Solid Dosage Forms
      • Oral Pharmaceuticals
        • Integrated project development
        • Project design planning
      • Oral Nutraceuticals
        • Integrated project development
        • Project design planning
      • Oral Medical Devices
        • Integrated project development
        • Project design planning
    • Non-Solid Dosage Forms
      • Topical Pharmaceuticals
        • Integrated project development
        • Project design planning
      • Topical Dermocosmetics
        • Integrated project development
        • Project design planning
      • Topical Medical Devices
        • Integrated project development
        • Project design planning
    • Analytical Services
    • Certifications
  • Media
    • Presentations
    • Press Releases
  • Contacts
    • Location
    • Vigilance
    • APR LAB

TOPICAL PHARMACEUTICALS
Integrated project development

Galenic development

Project design
planning

> Pre-formulation development: physical and chemical characteristics of the proposed drug are analyzed to allow selection of optimal excipients and dosage forms.

> Formulation design: based on the product's physicochemical/release characteristics and other important aspects, a range of theoretical formulations is proposed to determine how they affect the final product's characteristics such as in vitro/in vivo performance and stability.

> Compatibility tests: If necessary a compatibility test (i.e. stability at stressed condition) can be conducted in order to determine functional ingredients/excipient compatibility.

> Prototype development: APR's contract development team develop a prototype in the laboratory using data from pre-formulation development/design and compatibility tests. Generally, only minor modifications to the prototype are required when the process is scaled up to large-scale manufacturing

> Preliminary stability studies: using International Conference on Harmonization (ICH) guidelines and validated analytical methods, the prototype is tested to determine if the selected formulation(s) can be considered stable in terms of chemical , physical and microbiological point of view. The exact nature of tests carried out depends on the product and individual customer requests.

TOPICAL PHARMACEUTICALS
Integrated project development

Up-scaling
and validation

Project design
planning

APR manages all steps in the transfer to GMP facility (technical and analytical transfers) and the activities are the following:

> Up-scaling: Usually, before the preparation of the GMP Batch is necessary the preparation of an up-scaled batch.

> Production of batch according to GMP for clinical purpose: If required a GMP Batch for a clinical purpose is manufactured as well as the formal analytical validations. On the GMP Batch a stability study according to the ICH guidelines is then performed.

> Validation: is completed with the manufacture of three validation batches.

TOPICAL PHARMACEUTICALS
Integrated project development

Clinical Phase

Project design
planning

APR has a dedicated clinical department that is involved in all stages of the clinical trial program from designing protocols to supervision, monitoring and conduction of clinical studies. We work with a network of existing partners and/or those selected by our clients.

TOPICAL PHARMACEUTICALS
Integrated project development

Registration

Project design
planning

APR prepares Common Technical Document (CTD) for submission to the relevant regulatory bodies for approval/registration.

Project design
planning

Topical Medical Devices Topical Dermocosmetics
APR 2015 all rights reserved | About us | APR Products | Our services | News & Events | Contact | Privacy policy | Cookie policy | Sitemap